What's Happening?
On October 22, 2026, the U.S. Department of Justice (DOJ) Civil Division and the U.S. Department of Health and Human Services (HHS), including its Office of the General Counsel, Office of Inspector General (HHS-OIG), and the Centers for Medicare and Medicaid
Services (CMS), jointly announced the Healthcare False Claims Act Self-Disclosure Pilot Program (FCA SDPP). This six-month initiative aims to provide a clear and predictable pathway for legitimate American healthcare businesses to resolve civil liability under the federal False Claims Act (FCA) and specific HHS administrative authorities. The program allows companies to achieve a coordinated civil release without factual admissions and offers relief from several significant HHS administrative remedies. Submissions for the program are due by April 22, 2027. To be eligible, the disclosure must involve a potential FCA violation previously unknown to the federal government. Companies must also describe the conduct, identify violated laws and regulations, provide supporting documents, detail remedial measures taken, and submit financial information for repayment calculation. A certification from an authorized representative affirming the truthfulness and completeness of the submission is also required.
Why It's Important?
This pilot program is significant for the U.S. healthcare sector as it offers a structured and potentially less punitive route for companies to address past civil violations of the False Claims Act. By providing a coordinated civil release and waiving requirements for corporate integrity agreements and certain civil monetary penalties, HHS and DOJ are incentivizing self-reporting. This could lead to increased transparency and compliance within the healthcare industry, as companies may be more willing to come forward with potential violations if the consequences are predictable and less severe than traditional enforcement actions. The program's benefits, such as a repayment multiplier significantly lower than the treble damages typically available under the FCA, could save healthcare businesses substantial financial penalties. This initiative also streamlines the resolution process, preventing companies from having to report the same conduct through multiple civil self-disclosure programs. The emphasis on remedial measures encourages companies to proactively strengthen their compliance programs, ultimately benefiting the integrity of federal healthcare programs and protecting taxpayer dollars.
What's Next?
Healthcare companies with known or suspected compliance issues related to the False Claims Act have until April 22, 2027, to submit their self-disclosures under the FCA SDPP. Companies must act quickly to gather all necessary documentation, including details of the conduct, remedial actions, and financial information, as late or partial submissions will not be accepted. Legal counsel will be crucial in evaluating whether participation in this pilot program or the criminal self-disclosure policy is the most appropriate course of action. The success of this six-month pilot program will likely be assessed by the DOJ and HHS, potentially leading to its extension, modification, or establishment as a permanent fixture in healthcare enforcement. The program's impact on the volume of self-disclosures and the overall compliance landscape within the healthcare industry will be closely monitored by stakeholders, including government agencies, legal professionals, and healthcare providers.
Beyond the Headlines
The FCA SDPP reflects a broader shift in government enforcement strategies, moving towards encouraging voluntary compliance through structured incentives rather than solely relying on punitive measures. This approach acknowledges the complexity of healthcare regulations and the potential for inadvertent violations. By offering a 'clean slate' and predictable outcomes, the program aims to foster a culture of proactive compliance within the healthcare industry. However, the strict eligibility criteria, particularly the requirement that the conduct be previously unknown to the federal government, underscores the importance of continuous internal monitoring and prompt action. The program also highlights the increasing sophistication of government oversight, with agencies expanding whistleblower incentives and utilizing advanced data analytics to detect fraud. This means that companies that fail to proactively identify and address compliance issues may find themselves ineligible for such favorable resolution programs in the future, facing more severe penalties under traditional enforcement mechanisms.













